Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
-
Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer .
-
Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052
-
Aclaris Therapeutics to Participate in Two March Healthcare Conferences
-
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update
-
New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3
-
Aclaris Therapeutics announces formation of new scientific advisory board
-
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference